Signe Biopharma Inc.
Records under this name other than patents Signe Biopharma Inc. holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned.
Showing 1 to 6 of 6 · Back to Signe Biopharma Inc.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 8,563,249 | Receptor gene screening for detecting or diagnosing cancer Lapsed on the fee record Ended Oct 22, 2017 · USPTO record | Lapsed on the fee record | Ended Oct 22, 2017 | USPTO record |
| US 8,119,138 | Anti-Estrogen and Immune Modulator Combinations for Treating Breast Cancer Lapsed on the fee record Ended Feb 21, 2016 · High confidence | Lapsed on the fee record | Ended Feb 21, 2016 | High confidence |
| US 8,038,999 | Breast cancer eradication program Lapsed on the fee record Ended Oct 18, 2015 · USPTO record | Lapsed on the fee record | Ended Oct 18, 2015 | USPTO record |
| US 7,947,275 | Compositions and Methods for Demonstrating Secretory Immune System Regulation of Steroid Hormone Responsive Cancer Cell Growth Lapsed on the fee record Ended May 24, 2015 · Medium confidence | Lapsed on the fee record | Ended May 24, 2015 | Medium confidence |
| US 7,947,463 | Compositions and Methods for the Diagnosis, Treatment and Prevention of Steroid Hormone Responsive Cancers Lapsed on the fee record Ended May 24, 2015 · Medium confidence | Lapsed on the fee record | Ended May 24, 2015 | Medium confidence |
| US 7,863,011 | Screening Method for Predicting Susceptibility to Breast Cancer Lapsed on the fee record Ended Jan 4, 2015 · High confidence | Lapsed on the fee record | Ended Jan 4, 2015 | High confidence |